RCEL AVITA Medical, Inc.companySEC Filings & Insider Trading Activity 2026
Latest AVITA Medical, Inc. (RCEL) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 12, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on May 1, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for AVITA Medical, Inc. (RCEL) (SEC CIK 1762303), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Multi-product acute wound care platform focused on autologous cell harvesting technology RECELL plus complementary wound matrices
- • New products: Commercial launch of Cohealyx collagen dermal matrix (Apr 2025) and FDA approval/commercial rollout of RECELL GO mini for smaller wounds (Dec 2024)
Risk Factors
- • Regulatory risk: dependency on FDA PMA for RECELL, risk of modification/suspension/revocation impacting U.S. operations
- • Macroeconomic risk: $60M five-year senior secured credit facility with Perceptive, subject to net revenue covenants and rising interest rate exposure
Management Discussion & Analysis
- • Revenue $71.6M in 2025, up 11% YoY from $64.3M in 2024, driven by deeper penetration and new accounts
- • Gross margin 82.1% in 2025 vs 85.8% in 2024; decrease due to product mix and higher inventory reserve
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • No new risk factors added this quarter; risk profile unchanged since 2024 Annual Report
- • No material updates to existing risks since prior 10-K and Q1 2025 10-Q filings
Annual Reports Archive10-K
AI-powered analysis of AVITA Medical, Inc. (RCEL) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of AVITA Medical, Inc. (RCEL) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | — | $50.1M | $64.3M | $71.6M |
| Gross Profit | $28.4M | $42.4M | $55.2M | $58.8M |
| Operating Income | — | -$42.7M | -$56.6M | -$42.5M |
| Net Income | — | -$35.4M | -$61.8M | -$48.6M |
| Gross Margin | — | 84.5% | 85.8% | 82.1% |
| Op. Margin | — | -85.1% | -88.1% | -59.4% |
| Net Margin | — | -70.6% | -96.3% | -67.8% |
| Balance Sheet | ||||
| Total Assets | $98.3M | $111.6M | $79.7M | $56.4M |
| Equity | — | $49.1M | $4.5M | -$16.6M |
| ROE | — | -72.1% | -1374.6% | 291.8% |
Source: XBRL financial data from AVITA Medical, Inc. (RCEL) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | May 1, 2026 | — | — | — |
10-K | Feb 12, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 12, 2026 | — | — | |
8-K | Jan 13, 2026 | — | — | |
8-K | Jan 5, 2026 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 8, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 13, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 13, 2024 | Mar 31, 2024 | — | |
10-K | Feb 22, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 10, 2023 | Jun 30, 2023 | — | |
10-Q | May 11, 2023 | Mar 31, 2023 | — | |
10-K | Feb 23, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 10, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 11, 2022 | Jun 30, 2022 | — | |
10-Q | May 12, 2022 | Mar 31, 2022 | — | |
10-Q | Nov 8, 2021 | Sep 30, 2021 | — | |
10-K | Aug 26, 2021 | Jun 30, 2021 | — | |
10-Q | May 13, 2021 | Mar 31, 2021 | — | |
10-Q | Feb 16, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 10, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest RCEL SEC filings in 2026?
AVITA Medical, Inc. (RCEL) has filed a 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on May 1, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did RCEL file its most recent 10-K annual report?
AVITA Medical, Inc. (RCEL) filed its most recent 10-K annual report on February 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view RCEL 10-Q quarterly reports?
AVITA Medical, Inc. (RCEL)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every RCEL 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has RCEL filed recently?
AVITA Medical, Inc. (RCEL)'s most recent 8-K was filed on May 1, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find RCEL insider trading activity (Form 4)?
SignalX aggregates every RCEL Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does RCEL file with the SEC?
AVITA Medical, Inc. (RCEL) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new RCEL filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for AVITA Medical, Inc. (RCEL).
What is RCEL's SEC CIK number?
AVITA Medical, Inc. (RCEL)'s SEC CIK (Central Index Key) number is 1762303. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1762303 to look up all RCEL filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find RCEL return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from AVITA Medical, Inc. (RCEL) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of AVITA Medical, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 27+ filings.